|
|
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
Florence Ader
,
Nathan Peiffer-Smadja
,
Julien Poissy
,
Maude Bouscambert-Duchamp
,
Drifa Belhadi
,
et al.
Article dans une revue
hal-03364426v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study
Mathurin Fumery
,
Stéphane Nancey
,
Jérôme Filippi
,
Romain Altwegg
,
Xavier Hébuterne
,
et al.
Article dans une revue
hal-04012020v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Cancer-associated thrombosis: how many patients seen in clinical practice would be eligible to a randomized controlled trial?
B. Petit
,
S. Soudet
,
G. Poenou
,
E. Zarrat
,
T. Machuron
,
et al.
Thrombosis Research, 2022, 213 (2), pp.S30
Article dans une revue
hal-03679317v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Cancer Associated Thrombosis:how many lung cancer patients seen in clinical practice would be eligible to a DOAC randomized controlled trial?
B Petit
,
V Mismetti
,
S Soudet
,
G Poenou
,
E Zarrat
,
et al.
Article dans une revue
hal-04021110v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
Paul Bastard
,
Adrian Gervais
,
Tom Le Voyer
,
Jeremie Rosain
,
Quentin Philippot
,
et al.
Article dans une revue
hal-03358792v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|